Virttu offers oncolytic virus access
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum. Accessible to researchers in institutes and biotechnology and pharmaceutical companies, the REPLICATE Open Innovation Forum aims to stimulate development of new oncology combination therapies by providing access to Virttu's oncolytic virus, SEPREHVIR- (HSV1716).
According to Virttu CEO Steven Powell, there are many benefits to potential partners in joining Virttu REPLICATE Open Innovation Forum: "In recent years we have been approached regularly by research groups interested in investigating the use of SEPREHVIR- in oncology indications, either as a monotherapy or in combination with other treatment modalities. With interest in oncolytic viruses continuing to grow, establishing a formal collaborative network seemed the most efficient way forward. By joining Virttu REPLICATE, researchers gain access to latest data and insights into the use of oncoviruses and access to SEPREHVIR- - an engineered herpes simplex virus which is highly lytic, has a broad tissue tropism, replicates selectively in cancer cells and with safety demonstrated in man. In due course we believe this new and innovative initiative will lead to exciting opportunities to create breakthrough research and combination therapies with real clinical impact. "